Augustinus Bader,1 Martin Reinhardt,1 Achim Beuthe,Klaus Röhl,2 Shibashish Giri1,3

1Department of Cell Techniques and Applied Stem Cell Biology, Centre for Biotechnology and Biomedicine, Medical faculty of University of Leipzig, Leipzig, 2Department of Orthopedic Surgery, BG clinics Bergmannstrost Halle, 3Department of Plastic and Hand Surgery, University Hospital Rechts der Isar, Munich Technical University, Munich, Germany

Abstract: Spinal cord injury is a rare disease with an incidence about 40 cases per million population in the USA. The most common reasons are traffic accidents, falls, violence and sports. A 53-year-old male patient presented with an incomplete tetraparesis as a result of a spinal cord injury after a boat accident. It was not possible to treat him with steroids because he was out of the therapeutic time period of 8 hours when he presented to the hospital. The main problem of spinal cord injuries is the secondary injury caused by inflammation and swelling of the spinal cord. To avoid this, the patient was experimentally treated with erythropoietin (EPO) intrathecal and EPO, granulocyte-colony-stimulating factor and vitamin C subcutaneous after his initial spinal cord relief surgery. These drugs might be able to relieve this secondary reaction but were never applied for this indication in human before. This study shows that it could be a promising treatment for spinal cord injuries with potential therapeutic benefits.


Authors Bader A, Reinhardt M, Beuthe A, Röhl K, Giri S

Received 19 December 2016

Accepted for publication 4 July 2017

Published 27 November 2017 Volume 2017:13 Pages 1183—1188

DOI https://doi.org/10.2147/TCRM.S130627